In vitro effects of pirfenidone on cardiac fibroblasts: Proliferation, myofibroblast differentiation, migration and cytokine secretion

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Shi, Qiang ^a   Liu, Xiaoyan ^a   Bai, Yuanyuan ^a   Cui, Chuanjue ^a   Li, Jun ^a   Li, Yishi ^a   Hu, Shengshou ^a   Wei, Yingjie ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; GELATINASE B; INTERLEUKIN 1; PIRFENIDONE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; ACTIN; CYTOKINE; PYRIDONE DERIVATIVE; SMOOTH MUSCLE ACTIN, RAT;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FIBROBLAST; GENE EXPRESSION; HEART MUSCLE CELL; MIGRATION INHIBITION; MYOFIBROBLAST; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; RAT; ANIMAL; CELL MOTION; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; HEART MUSCLE; METABOLISM; SECRETION; SPRAGUE DAWLEY RAT;

ANIMALIA; RATTUS;

ACTINS; ANIMALS; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN; CYTOKINES; MATRIX METALLOPROTEINASE 9; MYOCARDIUM; MYOFIBROBLASTS; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 81755184093     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028134     Document Type: Article

References (54)

1. Cohn JN, Ferrari R, Sharpe N, (2000) Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 35: 569-582.
2. Porter KE, Turner NA, (2009) Cardiac fibroblasts: At the heart of myocardial remodeling. Pharmacology & Therapeutics 123: 255-278.
3. Souders CA, Bowers SLK, Baudino TA, (2009) Cardiac Fibroblast: The Renaissance Cell. Circulation Research 105: 1164-1176.
4. Towbin JA, (2007) Scarring in the heart--a reversible phenomenon? N Engl J Med 357: 1767-1768.
5. Baudino TA, Carver W, Giles W, Borg TK, (2006) Cardiac fibroblasts: friend or foe? Am J Physiol Heart Circ Physiol 291: H1015-1026.
6. Brown RD, Ambler SK, Mitchell MD, Long CS, (2005) The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 45: 657-687.
7. Serini G, Gabbiani G, (1999) Mechanisms of myofibroblast activity and phenotypic modulation. Exp Cell Res 250: 273-283.
8. Eghbali M, (1992) Cardiac fibroblasts: function, regulation of gene expression, and phenotypic modulation. Basic Res Cardiol 87 (Suppl 2): 183-189.
9. Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, et al. (2008) Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 590: 400-408.
10. Kakugawa T, Mukae H, Hayashi T, Ishii H, Abe K, et al. (2004) Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur Respir J 24: 57-65.
11. Card JW, Racz WJ, Brien JF, Margolin SB, Massey TE, (2003) Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity. Toxicol Sci 75: 169-180.
12. Leh S, (2004) Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats. Nephrology Dialysis Transplantation 20: 71-82.
13. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, et al. (2001) Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 133: 687-694.
14. Tada S, Nakamuta M, Enjoji M, Sugimoto R, Iwamoto H, et al. (2001) Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clin Exp Pharmacol Physiol 28: 522-527.
15. Nguyen DT, Ding C, Wilson E, Marcus GM, Olgin JE, (2010) Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias. Heart Rhythm 7: 1438-1445.
16. Lee KW, Everett THt, Rahmutula D, Guerra JM, Wilson E, et al. (2006) Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 114: 1703-1712.
17. Mirkovic S, Seymour AM, Fenning A, Strachan A, Margolin SB, et al. (2002) Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. Br J Pharmacol 135: 961-968.
18. Dosanjh AK, Wan B, Throndset W, Sherwood S, Morris RE, (1998) Pirfenidone: a novel antifibrotic agent with implications for the treatment of obliterative bronchiolitis. Transplant Proc 30: 1910-1911.
19. Lee BS, (1998) Pirfenidone: A Novel Pharmacological Agent That Inhibits Leiomyoma Cell Proliferation and Collagen Production. Journal of Clinical Endocrinology & Metabolism 83: 219-223.
20. Lin X, Yu M, Wu K, Yuan H, Zhong H, (2009) Effects of pirfenidone on proliferation, migration, and collagen contraction of human Tenon's fibroblasts in vitro. Invest Ophthalmol Vis Sci 50: 3763-3770.
21. Visner GA, Liu F, Bizargity P, Liu H, Liu K, et al. (2009) Pirfenidone Inhibits T-Cell Activation, Proliferation, Cytokine and Chemokine Production, and Host Alloresponses. Transplantation 88: 330-338.
22. Di Sario A, Bendia E, Svegliati Baroni G, Ridolfi F, Casini A, et al. (2002) Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J Hepatol 37: 584-591.
23. Hewitson TD, Kelynack KJ, Tait MG, Martic M, Jones CL, et al. (2001) Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J Nephrol 14: 453-460.
24. Kaneko M, Inoue H, Nakazawa R, Azuma N, Suzuki M, et al. (1998) Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts. Clin Exp Immunol 113: 72-76.
25. Nakayama S, Mukae H, Sakamoto N, Kakugawa T, Yoshioka S, et al. (2008) Pirfenidone inhibits the expression of HSP47 in TGF-β1-stimulated human lung fibroblasts. Life Sciences 82: 210-217.
26. Nakazato H, Oku H, Yamane S, Tsuruta Y, Suzuki R, (2002) A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol 446: 177-185.
27. Lu B, Mahmud H, Maass AH, Yu B, van Gilst WH, et al. (2010) The Plk1 inhibitor BI 2536 temporarily arrests primary cardiac fibroblasts in mitosis and generates aneuploidy in vitro. PLoS One 5: e12963.
28. Porter KE, Naik J, Turner NA, Dickinson T, Thompson MM, et al. (2002) Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg 36: 150-157.
29. Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, et al. (1995) Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med 125: 779-785.
30. Gurtner GC, Werner S, Barrandon Y, Longaker MT, (2008) Wound repair and regeneration. Nature 453: 314-321.
31. Desmouliere A, Redard M, Darby I, Gabbiani G, (1995) Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol 146: 56-66.
32. Frangogiannis NG, (2006) Targeting the inflammatory response in healing myocardial infarcts. Curr Med Chem 13: 1877-1893.
33. Sun Y, Weber KT, (2000) Infarct scar: a dynamic tissue. Cardiovasc Res 46: 250-256.
34. Peterson JT, Hallak H, Johnson L, Li H, O'Brien PM, et al. (2001) Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 103: 2303-2309.
35. Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, et al. (1999) Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99: 3063-3070.
36. Wilson EM, Gunasinghe HR, Coker ML, Sprunger P, Lee-Jackson D, et al. (2002) Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail 8: 390-398.
37. Li YY, Feldman AM, Sun Y, McTiernan CF, (1998) Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 98: 1728-1734.
38. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, et al. (2000) Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106: 55-62.
39. Wang Y, Xu F, Chen J, Shen X, Deng Y, et al. (2011) Matrix metalloproteinase-9 induces cardiac fibroblast migration, collagen and cytokine secretion: Inhibition by salvianolic acid B from Salvia miltiorrhiza. Phytomedicine In press.
40. Spinale FG, (2002) Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 90: 520-530.
41. Wei Y, Cui C, Lainscak M, Zhang X, Li J, et al. (2011) Type-specific dysregulation of matrix metalloproteinases and their tissue inhibitors in end-stage heart failure patients: relationship between MMP-10 and LV remodelling. J Cell Mol Med 15: 773-782.
42. Rosenkranz S, (2004) TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 63: 423-432.
43. Petrov VV, Fagard RH, Lijnen PJ, (2000) Transforming growth factor-beta(1) induces angiotensin-converting enzyme synthesis in rat cardiac fibroblasts during their differentiation to myofibroblasts. J Renin Angiotensin Aldosterone Syst 1: 342-352.
44. Lijnen P, Petrov V, Rumilla K, Fagard R, (2003) Transforming growth factor-beta 1 promotes contraction of collagen gel by cardiac fibroblasts through their differentiation into myofibroblasts. Methods Find Exp Clin Pharmacol 25: 79-86.
45. Burghardt I, Tritschler F, Opitz CA, Frank B, Weller M, et al. (2007) Pirfenidone inhibits TGF-beta expression in malignant glioma cells. Biochem Biophys Res Commun 354: 542-547.
46. Garcia L, Hernandez I, Sandoval A, Salazar A, Garcia J, et al. (2002) Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol 37: 797-805.
47. Shihab FS, Bennett WM, Yi H, Andoh TF, (2002) Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant 2: 111-119.
48. Iyer SN, Gurujeyalakshmi G, Giri SN, (1999) Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 291: 367-373.
49. Shimizu T, Kuroda T, Hata S, Fukagawa M, Margolin SB, et al. (1998) Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int 54: 99-109.
50. Oku H, Nakazato H, Horikawa T, Tsuruta Y, Suzuki R, (2002) Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol 446: 167-176.
51. Lan L, Chen Y, Sun C, Sun Q, Hu J, et al. (2008) Transplantation of bone marrow-derived hepatocyte stem cells transduced with adenovirus-mediated IL-10 gene reverses liver fibrosis in rats. Transpl Int 21: 581-592.
52. Wilson MS, Elnekave E, Mentink-Kane MM, Hodges MG, Pesce JT, et al. (2007) IL-13Ralpha2 and IL-10 coordinately suppress airway inflammation, airway-hyperreactivity, and fibrosis in mice. J Clin Invest 117: 2941-2951.
53. Mu W, Ouyang X, Agarwal A, Zhang L, Long DA, et al. (2005) IL-10 suppresses chemokines, inflammation, and fibrosis in a model of chronic renal disease. J Am Soc Nephrol 16: 3651-3660.
54. Li Z, Wei H, Deng L, Cong X, Chen X, (2010) Expression and secretion of interleukin-1beta, tumour necrosis factor-alpha and interleukin-10 by hypoxia- and serum-deprivation-stimulated mesenchymal stem cells. FEBS J 277: 3688-3698.